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Abstract
Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of cancers,
particularly colorectal carcinoma, and developed to be a molecular target for cancer diagnosis and therapy. In present
study, we generated a novel anti-CEACAM5 monoclonal antibody, namely mAb CC4, by immunizing mice with living
colorectal cancer LS174T cells. Immunohistochemical studies found that mAb CC4 specifically and strongly binds to tumor
tissues, especially colorectal adenocarcinoma. In xenografted mice, mAb CC4 is specifically accumulated in tumor site and
remarkably represses colorectal tumor growth. In vitro functional analysis showed that mAb CC4 significantly suppresses cell
proliferation, migration and aggregation of colorectal cancer cells and also raises strong ADCC reaction. More interestingly,
mAb CC4 is able to enhance NK cytotoxicity against MHC-I-deficient colorectal cancer cells by blocking intercellular
interaction between epithelial CEACAM5 and NK inhibitory receptor CEACAM1. These data suggest that mAb CC4 has the
potential to be developed as a novel tumor-targeting carrier and cancer therapeutic.
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Introduction
After the discovery of Carcinoembryonic antigen (CEA,
CEACAM5, and CD66e) as a tumor-associated antigen in human
colon cancer [1], CEACAM5 has been found over-expressed in a
high percentage of human tumors, including 90% of gastrointes-
tinal, colorectal and pancreatic cancers, 70% of non-small cell
lung cancer cells and 50% of breast cancers [2]. High levels of
CEACAM5 have also been implicated with enhanced metastasis
and the development of malignancy [3,4]. Owing to its ectopic
expression and correlation with metastatic potential in cancers,
particularly colorectal cancer, CEACAM5 measurement has been
widely applied in clinical detection of liver metastasis from colo-
rectal cancers and post-surgical surveillance of colon cancer [5,6].
Belonging to the CEACAM (CEA-related Cell Adhesion Molec-
ule) family, a prominent group in the immunoglobulin superfamily
of cell adhesion molecules (IgCAMs), CEACAM5 mainly serves as
a cell adhesion molecule mediating intercellular contact by both
homophilic (CEACAM5 to CEACAM5) binding and heterophilic
binding (CEACAM5 to CEACAM1 or CEACAM6). These inter-
actions are predominantly mediated by the N-terminal IgV-like
domain [7], which is conserved among all the CEACAM family
members. Besides its functions in cell adhesion and migration,
CEACAM5 also inhibits anoikis [8], apoptosis in the absence of
adhesive interactions with extracellular matrix (ECM). Since resis-
tancetoanoikisisa characteristicoftumorcells,inhibitionofanoikis
by CEACAM5 suggests its role in facilitating tumorigenesis and
metastasis. Indeed, the tumorigenic functions of CEACAM5 had
been demonstrated in both 3D culture of colon carcinoma cell lines
in vitro [9] and CEABAC transgenic mice in vivo [10,11]; and a
number of studies evidenced the contribution of CEACAM5 to
tumor invasion and metastasis [3,4].
Targeting the tumor-associated expression and oncogenic func-
tions of CEACAM5, a pile of monoclonal antibodies against CE-
ACAM5 have been developed in previous years to facilitate the
diagnosis and therapy of human cancers. However, most of these
therapeutic antibodies were conjugated with radioisotype, immu-
notoxin, cytokine or cytotoxic enzyme [12,13,14,15], which lead
to considerable side effects. The availability of natural anti-CE-
ACAM5 mAbs with significant tumor-targeting and -suppressing
activity is still limited. In this paper, we report a novel anti-CE-
ACAM5mAb,namelyCC4,whichspecificallyaccumulatesintumor
tissues and remarkably inhibits tumor growth of colorectal cancer
both in vivo and in vitro.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21146CEACAM1, one of the binding partners of CEACAM5 in the
CEACAM family, has been implicated in contact-dependent regula-
tion of immune response associated with cancer [16]. CEACAM1
contains two ITIM sequences located within its cytoplasmic tail
and was found expressed on CD16-negative NK cells as a class I
MHC-independent inhibitory receptor [17]. Homophilic CEA-
CAM1 interactions between a MHC-I-deficient melanoma cell
line (1106mel) and NK cells significantly inhibited NK killings
against cancer cells [17]. Moreover, forced expression of CEA-
CAM5 in HLA class I-defective 721.221 cells also suppressed NK
cytotoxicity [18], indicating CEACAM5-CEACAM1 heterophilic
interaction is also able to trigger inhibitory CEACAM1 signaling
in NK cells. However, the function of CEACAM5 in inhibiting the
killings by CD16-negative NK cells has never been tested in colo-
rectal cancer, in which CEACAM5 displays the highest patho-
logical expression. In present study, we show that the same tumor
immune escape mechanism also exists in human colorectal cancer
and mAb CC4 can significantly block the inhibition of NK
cytotoxicity by interfering with the CEACAM5-CEACAM1 inter-
cellular interaction.
Results
Generation and characterization of mAb CC4
Monoclonal antibody CC4 was generated by immunizing mice
with living human colorectal cancer cells, LS174T, and it showed
strong binding to fixed LS174T cells in primary cell-ELISA screens.
Several experiments were then performed to characterize mAb
CC4 at the biochemical, cellular and histological levels. First of all,
the binding of mAb CC4 to living LS174T cells was confirmed by
flow cytometry analysis (Figure 1A), and immunofluorescence showed
mAb CC4 recognizes a membrane-bound protein on cell surfaces
(Figure 1B). Immunohistochemical analysis showed the specific re-
cognition of mAb CC4 to colorectal tumor, particularly epithelial
Figure 1. Characterization of mAb CC4 and identification of mAb CC4 antigen. MAb CC4 was used to stain LS174T cells in flow cytometry
assay (A) and immunofluorescence (B). Isotype-matched murine normal IgG served as negative control. Frozen sections of normal colon and
colorectal tumor tissues were stained by mAb CC4 in immunohistochemical analysis (C); and extracts from these tissues and whole cell extracts of
LS174T and SW1116 were subjected to immunoblot using mAb CC4 (D, lower panels). LS174T cell lysate were immunoblotted with CC4 under
reduced or non-reduced conditions (D, upper panels). Immunoprecipitation was performed using mAb CC4 or mIgG to accumulate the antigen
protein and immunoprecipitates were subjected to Western blot assays (E). Four peptides were obtained from LC-MS analysis using CC4 precipitates
and the antigen was identified as CEACAM5, of which partial amino acid sequence and these identified peptides were illustrated (F). Bladder cancer
cells T2-4 were transfected with CEACAM5 expression plasmids and subjected to flow cytometry analysis with CC4 (G).
doi:10.1371/journal.pone.0021146.g001
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patient (Figure 1C). Western blot assays with tissue extracts con-
firmed the remarkably stronger binding of mAb CC4 to tumor than
normal tissues (Figure 1D, lower panel). Cell lysates from LS174T
and SW1116, another colorectal cancer cell line, were also recog-
nized by mAb CC4 in immunoblot assays (lane 3 and 4). Fur-
thermore, mAb CC4 recognizes the antigen under both reducing
andnon-reducingconditions,suggestingalinearepitope(Figure1D,
upper panel).
Tumor specificity of mAb CC4
Bindings of mAb CC4 to various types of cancer cells were
studied by flow cytometry and immunofluorescence (Table S1),
and we found that all of the nine tested colorectal cancer cell lines
were positive for CC4 staining. We then screened both normal
and tumor tissues from several major body organs by immuno-
histochemistry. MAb CC4 did not stain or only slightly stained
normal tissues with a frequency of staining of 31.71% (13/41,
Table S2) compared to a remarkably strong recognition in 71.88%
(69/96, Table S2) of various tumor tissues. Specially, all the sec-
tions from digestive system cancers tested, including colorectal car-
cinoma, gastric carcinoma and esophageal cancer were positive for
mAb CC4 staining, whereas just 22% normal colon tissues were
observably stained. Thus, these data indicated the specificity of
mAb CC4 to digestive system tumors, particularly colorectaltumors
at both cellular and histological levels.
Antigen identification of mAb CC4
To identify the antigen recognized by mAb CC4, whole cell
lysates from LS174T cells was immunoprecipitated by mAb CC4,
and the captured antigen was then tested in Western blot assay
(Figure 1E) and subjected to proteomic analysis. After trypsin diges-
tions, four tryptic peptides (1-VDGNRQIIGYVIGTQQATPGP-
AYSGR, 2-QIIGYVIGTQQATPGPAYSGR, 3-SDLVNEEATG-
QFR, and 4-RSDSVILNVLYGPDAPTISPLNTSYR) were iden-
tified by mass spectrometry (Figure 1F). Database searching revealed
that the only protein containing these sequences is carcinoembryonic
antigen-related cell adhesion molecule 5 (CEACAM5, CEA or
CD66e). The binding of mAb CC4 to bladder cancer T2-4 cells
transfected with CEACAM5-expressing vectors further validated
the recognition of mAb CC4 to CEACAM5 (Figure 1G).
Specific targeting of mAb CC4 to tumor in vivo
After identifying the antigen of this cancer-specific monoclonal
antibody, we then employed an in vivo model to test whether mAb
CC4 could specifically target the tumor in xenografted mice. A
widely used non-small cell lung cancer cell line A549 was engaged
in this study and confirmed to be positive for mAb CC4 staining in
immunofluorescence assays (Figure 2A). 2610
7 A549 cells were
injected to form a 6-8 mm-diameter tumor in nude mouse. Tumor-
bearing mice then received intravenous injection of Cy5-labeled
CC4 antibody or Cy5-conjugated IgG and monitored by fluores-
cence reflectance imaging system. As shown in Figure 2B, mAb
CC4 was amazingly accumulated in the tumor site within just
8 hours after the injection. The tumor/skin contrast reached as
high as 4 in 2 days and the high contrast lasted more than a week.
However, the negative control, Cy5-IgG, was only found to under-
go protein metabolism in liver and these control mice maintained
a low tumor/skin contrast as the background (Figure 2C). These
optical imaging data in an in vivo tumor-bearing mice model
exhibit a very exciting capability of mAb CC4 in specifically tar-
geting tumors and raise the possibility of applying mAb CC4 in
clinical diagnosis.
Inhibition of human tumor growth in xenografted mice
by mAb CC4
We then tested the therapeutic potential of mAb CC4 against
human colorectal tumor in an in vivo system. Xenografts were
established by injecting colorectal cancer LS174T cells to nude
mice. These mice started to receive treatment of mAb CC4 or
normal mIgG, administrated intraperitoneally, when the tumor
reached a diameter of 3 to 5 mm. After observing both experi-
mental and control groups for more than a month, we found that
mice injected with mAb CC4 developed tumor as small as less
than 0.2 cm
3, however, tumors had grown to a very large size in
mice treated with mIgG (Figure 2D). These data indicated that just
naked mAb CC4, without being radiolabeled or anticancer agent-
conjugated, was able to remarkably suppress human tumor growth,
suggesting its application value in cancer therapy.
ADCC activity of mAb CC4
We next explored the mechanisms underlying the anti-tumor
activity of mAb CC4. First, we examined mAb CC49s activity of
inducing antibody-dependent cell cytotoxicity (ADCC), since it
was reported that anti-CEA mAb hMN-14 (labetuzumab) inhi-
bited colonic carcinoma growth mainly by raising ADCC reaction
[19]. Isolated murine spleen cells were used as effector cells, while
LS174T cells served as target cells. The ADCC activity of mAb
CC4 was measured by LDH release based on a Homogeneous
Membrane Integrity Assay. As shown in Figure 2E, mAb CC4
raised a strong cytotoxicity against LS174T cells by activating
murine immune cells, compared to normal mIgG, however, it had
no such effect on CC4-negative melanoma A375 cells. Therefore,
the marked inhibition of xenograft tumor growth in mice by mAb
CC4 could be partially explained by strong ADCC reactions.
mAb CC4 inhibits cell proliferation and blocks cell
migration and aggregation
We also examined the direct effects of mAb CC4 on colorectal
cancer cells growth in vitro.2 5mg/ml of mAb CC4 is capable of
significantly inhibiting the proliferation of CFSE-labeled colorectal
cancer LS174T and Lovo cells (Figure 3A and Figure 3B). Further
cell cycle analysis showed that mAb CC4 suppresses cell growth by
abrogating S/G2 transition and preventing more than 15% cells
from entering G2 phase (Figure S1). Growth of two other colo-
rectal tumor cell lines, Colo-205 and SW1116, was also found sup-
pressed by mAb CC4 (data not shown). Nevertheless, mAb CC4
does not markedly induce cancer cell apoptosis in TUNEL assays
(Figure S2).
CEACAM5 mediates cell-cell contact by homophilic and het-
erophilic interaction and is also involved in cell adhesion and mig-
ration [3,20]. Thus, we used chamber assay to find that mAb CC4
inhibited LS174T cells, Lovo cells and Colo-205 cells migration in
a dose-dependent manner (Figure 3C and Figure S3). Further-
more, in a standard cell aggregation assay, around eighty percent
of LS174T cells could not aggregate in the presence of 50 mg/ml
mAb CC4, whereas only 40% of cells maintained single when
treated with murine IgG (Figure 3Di). Adding chelating reagent
EGTA or CaCl2 could not affect the function of mAb CC4 in
blocking cell aggregation (Figure 3Dii), consistent with that CE-
ACAM5 belongs to immunoglobulin superfamily and mediates
Ca
2+-independent cell-cell adhesion. Since colorectal cancer cells
grow in aggregates morphologically in tissue culture, it is possible
that mAb CC4 mainly influences tumor cell growth by disturbing
cell-cell contact and interfering with signaling transduction. Simi-
lar results were also obtained in SW1116, Lovo and Colo-205 cells
(data not shown).
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Functions of mAb CC4 in directly affecting cell proliferation
and migration led us to speculate that it might recognize a distinct
epitope harboring key amino acids for the molecular functions.
CEACAM5 consists of seven extracellular Ig domains, of which
the N-terminal IgV-like domain is the most important and func-
tional part in mediating CEACAM5 homophilic and heterophilic
adhesions [7]. To test whether mAb CC4 could bind to the
Figure 2. mAb CC4 was able to target xenografted tumors, suppress tumor growth in vivo, and raised ADCC reactions in vitro. Non-
smallcell lung cancercellsA549 was stainedwith cy5labeled CC4 in immunofluorescence (A). Cellswere injected to nudemice to form tumors andCC4-
cy5or IgG-cy5 was administrated intravenously.Invivo opticalimaging of fluorescentantibodies was performed in theindicated times (BandC).LS174T
cells were injected subcutaneously into nude mice. After forming tumor, mice were treated with CC4 or normal IgG control for indicated times. Tumors
were taken out for measuring the size and calculating the volume, as well as photography (D, n=7 in each group, **P,0.01 and *P,0.05). LS174T cells
weresubjectedtoADCCassaysusingmurinespleen cellsaseffectorcells.Resultsforspecificcytotoxicityofcancercellswerepresentedinbargraphs(E).
doi:10.1371/journal.pone.0021146.g002
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tope mapping was performed using various extracellular fractions
and mutants of the protein (Figure 4A).
Three extracellular Ig domains proximal to the N-terminus, also
known as N, A1, and B1 domain, designated here as Domain1
(D1, aa35–155), Domain2 (D2, aa139–273) and Domain3 (D3,
230–355) respectively, were expressed; and only D1 was recog-
nized by mAb CC4, indicating the epitope is located in the region
of aa35–138 (Figure 4B). This region was further fractionized to
generate four fragments, F42–273, F62–273, F80–273, and F101–
273. Western blot results showed that mAb CC4 only bound to
F42–273, suggesting the epitope is harbored in a narrowed region,
aa42–61 (Figure 4C). These observations were then confirmed
using full-length CEACAM5 mutants lacking N-domain or aa42–
61. Flow cytometry assays showed that mAb CC4 could bind to
293T cells transfected with CEACAM5 but not cells expressing
either CEACAM5-DN or CEACAM5-D42-61 (Figure 4D). Rabbit
polyclonal anti-CEA antibody (RACEA) served as a positive
control for the transfection. Therefore, these results revealed that
the epitope of mAb CC4 is located in the functional N-domain of
CEACAM5, more specifically the region of aa42–61.
Moreover, since the amino acid sequence of the epitope recog-
nized by mAb CC4 is completely conserved between CEACAM5
and CEACAM1, mAb CC4 also binds to the 293T cells expressing
wild-type CEACAM1 but not the mutant lacking aa42–61 (Figure 4E).
The recognition of mAb CC4 to the same epitope in the N-domain
of both CEACAM5 and CEACAM1 implicated that mAb CC4
may not only block CEACAM5-CEACAM5 homophilic interac-
tions but also obstruct CEACAM1-CEACAM1 homophilic and
CEACAM1-CEACAM5 heterophilic associations.
Enhancement of NK killings against HLA-I
low colorectal
cancer cells by mAb CC4
Above findings led to the possibility that mAb CC4 may inter-
fere with the cell-cell contact between CEACAM1 expressed on
immune cells and CEACAM5 expressed on colorectal cancer cells.
In fact, both CEACAM1 and CEACAM5 expressed on melanoma
or 721.221 cells suppress NK cell-mediated cytotoxicity against
tumor cells by interacting with and activating NK CEACAM1,
which is a MHC I-independent inhibitory receptor [17,18]. How-
ever, this mechanism has not been tested in CEACAM5-over-
expressing colonic adenocarcinoma.
We first screened ten different colorectal cancer cell lines for
expression patterns of CEACAM5 and HLA-I by flow cytometry
analysis(TableS3),and chosefourcelllineswithdifferent expression
patterns for further studies, SW480 (CC4-, HLA-I
high), LS174T
Figure 3. mAb CC4 suppressed proliferation, migration and aggregation of colorectal cancer cells. LS174T cells treated with indicated
concentrations of mAb CC4 were subjected to proliferation assays using CFSE staining (A). The same assay was also performed using Lovo cells under
the treatment of 25 mg/ml mAb CC4 (B). LS174T cells were used in migration assays using transwell system (C) and aggragation assays in the
presence of indicated concentrations of mAb CC4 or normal mIgG (Di) with Ca
2+ or EGTA (Dii). Statistically significant differences between mAb CC4
treated groups and control groups were indicated by double stars (**P,0.01).
doi:10.1371/journal.pone.0021146.g003
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high), HCT-15 (CC4-, HLA-I
low) and Lovo (CC4+,
HLA-I
low). Both CD56+CD16+ and CD56+CD16- Human NK
cells were isolated from human PBMCs (peripheral blood mono-
nuclear cells) using magnetic cell sorting system. Cell types were
verified by staining with fluorescent antibodies and it was found
that only CD56+CD16- NK cells but not CD56+CD16+ cells
express CEACAM1 (Figure 5A and B). These NK cells were sub-
jected to cytotoxicity assays against various colorectal cancer cells.
In order to avoid any possible ADCC activity, mAb CC4 was di-
gested with pepsin and the resulted CC4 F(ab)2 fragment was used
in the experiments.
Owing to the high expression levels of HLA-I molecules both
SW480 and LS174T were not killed by NK cells, while HCT-15
cells lacking HLA-I were killed efficiently and adding CC4 F(ab)2
had no effect on cytotoxicity since HCT-15 does not express
CEACAM5 (Figure 5C and D). However, HLA-I-deficient but
CEACAM5-positive Lovo cells could not be readily killed by
CEACAM1-expressing CD56+CD16- NK cells; and the treat-
ment of CC4 F(ab)2 significantly enhanced the cytotoxicity against
Lovo cells by CD16- NK cells but not CD16+ NK cells. These
results indicated that mAb CC4 could specifically promote the
killing against CEACAM5-expressing cells by CEACAM1-ex-
pressing NK cells.
Disruption of CEACAM1-mediated inhibition of NK
activity by mAb CC4
To further verify that mAb CC4-enhanced NK killings is based
on the disruption of CEACAM1-CEACAM5 interaction between
NK and tumor cells. We transfected CEACAM1- and CEAC-
AM5-expressing plasmids into colorectal cancer HCT-15 cells,
respectively, and then generated stable cell lines, designated as
HCT-15/CEACAM1 and HCT-15/CEACAM5. Forced expres-
sions of these molecules in the transfectants were confirmed by
flow cytometry analysis (Figure 6A).
Increasing the expressions of either CEACAM1 or CEACAM5,
the ligand for NK CEACAM1, did not affect the killings against
cancer cells by CD56+CD16+ NK cells, since these cells do not
express CEACAM1 (Figure 6B). However, the cytotoxicity induced
by CEACAM1-expressing CD56+CD16- NK cells was significantly
compromised by ectopic expression of CEACAM1 or CEACAM5
in HCT-15 cells (Figure 6C and D). Thus, the tumor immune
evasion mechanism that up-regulation of CEACAM1 or CEA-
CAM5 activates inhibitory CEACAM1 signaling in NK cells and
then circumvents NK cytotoxicity also exists in colorectal cancer
cells.Moreimportantly,treatment ofCC4 F(ab)2 remarkablyblocked
the repression of NK killing activity caused by either CEACAM1
or CEACAM5 ectopic expression, suggesting that the effect ofmAb
Figure 4. Epitope mapping of mAb CC4. Recombinant CEACAM5 fractions and full-length deletion mutants were illustrated in (A). These
recombinant fractions were expressed in E. Coli and whole cell lysates were separated by SDS-PAGE and analyzed by immunoblot with anti-His-tag
(positive control) and mAb CC4 (B and C). Plasmid expressing full-length CEACAM5 wild-type or mutants were transfected into 293T cells and these
cells were then subjected to flow cytometry assays using mAb CC4 or rabbit polyclonal anti-CEA (RACEA) or mIgG (D). Amino acid sequences of
region aa42–61 of CEACAM1 and CEACAM5 were shown; and 293T cells were transfected with plasmids expressing CEACAM1 wt or mutant and
analyzed by flow cytometry with indicated antibodies (E).
doi:10.1371/journal.pone.0021146.g004
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buted to its function of specifically abrogating the initiation of
CEACAM1signalinginNKcells.Notably,mAb CC4 enhancesNK
cytotoxicity in a dose-dependent manner and has a comparable ac-
tivity as the neutralizing polyclonal antibodies RACEA.
Discussion
With the advantages of targeting tumor cells specifically, mono-
clonal antibodies against tumor-associated antigens provide great
opportunities for biological therapy of cancers. Following the dis-
covery of Carcinoembryonic antigen (CEA or CEACAM5) as a
colorectal cancer-associated antigen, anti-CEACAM5 mAbs have
been found effective in diagnosis and therapy of multiple types
of cancers. A humanized anti-CEACAM5 mAb, labetuzumab,
and human monoclonal antibodies (HmAbs) were found able to
suppress tumor growth and metastasis [21,22], while other mAbs
labeled with radioactive isotopes were applied for tumor imaging
[23,24]. However, nearly no single anti-CEACAM5 mAb has been
reported to have both tumor-targeting and tumor-suppressing
activities. In this study, we reported a novel anti-CEACAM5 mAb
CC4, which has striking capabilities of both targeting and accumu-
lating in tumor tissues in vivo and remarkable functions of inhibiting
tumor growth in animal models. These capacities of mAb CC4
make it a promising diagnostic tool as well as a potential therapeutic
for the treatment of cancers, particularly colorectal cancer.
Figure 5. mAb CC4 enhanced the killing of HLA-I
low colorectal cancer cells by CD16- NK cells. CD56+CD16+ (A) and CD56+CD16- NK cells
(B) isolated from human PBMCs were analyzed by flow cytometry. NK cytotoxicity assays were performed against various colorectal cancer cell lines
using either CD56+CD16+ (C) or CD56+CD16- (D) NK cells as effector cells. Significant differences between mAb CC4 treatments and controls were
indicated by double stars (**P,0.01).
doi:10.1371/journal.pone.0021146.g005
CEA mAb Inhibits Tumor Growth and Immune Escape
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21146CEACAM5 mainly mediates cell adhesion and enhances cell
migration through homophilic binding or heterophilic interaction
with other CEACAMs. These functions are disturbed by mAb
CC4 according to its capabilities of inhibiting cell aggregation and
transmigration. Interestingly, it was reported that intercellular
adhesion of CEACAM5 requires N-terminal IgV-like domain,
more precisely three subdomains: GYSWYK (aa64–69), NRQII
(aa76–80) and QNDTG (aa114–118) [7], while mAb CC4 recog-
nizes an epitope (aa42–61) very close to these amino acids. Thus,
the binding of mAb CC4 to CEACAM5 may interfere with its
interactions with itself or other CEACAMs structurally or topo-
logically. It is worth noting that 10 mg/ml of mAb CC4 is sufficient
to block cell aggregation whereas peptides targeting these sub-
domains need a much higher minimal concentration (1 mg/ml) to
block the adhesion [25]. High efficiency of mAb CC4 might
be attributed to its high stability and affinity to the interface of
CEACAM5 homophilic interactions.
Moreover, mAb CC4 also shows some interesting functions of
directly affecting tumor cell growth, such as suppressing colorectal
cancer cell proliferation. These properties were not observed in the
studies of other anti-CEACAM5 therapeutic mAbs, such as labe-
tuzumab [19]. Though there is a strong correlation between CE-
ACAM5 expression levels and tumor growth, little is known about
its role in promoting proliferation. It will be of interest to study
why mAb CC4 could influence cell proliferation through binding
to CEACAM5.
Tumor cells adopt various mechanisms to escape from cancer
immunosurveillance mediated by lymphocytes of both the adaptive
and innate immune compartments [26]. One of the widely found
strategies in tumor is the depletion or mutations of MHC class I
molecules in transformed cells in order to avoid presenting tumor
antigens and bypass the attack of adaptive immune systems [27].
However, NK cytotoxicity could be activated against these ‘‘non-
self’’ cells lacking specific class I MHC [28]. Identification of
CEACAM1 as a MHC-I-independent NK inhibitory receptors pro-
vided new insights toward understanding tumor immune evasion
mechanisms [17], since the binding partners of CEACAM1—
CEACAM1 itself and CEACAM5—are widely present in various
types of cancers. It was first identified in MHC-I-negative mela-
noma cells (1106mel) that expression of CEACAM1 blocked the
killing by CD16-CEACAM1+ NK cells [17]. In present study, we
found that some HLA-I-deficient colorectal cancer cells (Lovo)
present high levels of CEACAM5 and were resistant to the killings
by CD16-negative NK cells. Importantly, overexpression of either
CEACAM1 orCEACAM5 inCEACAM5-HLA-I
lowcolonic tumor
cells could prevent NK cytotoxicity against these cells. These data
indicated that similar mechanisms by which cancer cells lacking
class I MHC molecules express CEACAM1 ligands to suppress the
killing activity of NK cells are also adopted by colorectal tumor cells
and might be common in all kinds of cancers.
The finding that CEACAM5 protects tumor cells from NK
killing is rather significant in colorectal cancers since a very high
percentage of colonic adenocarcinomas display strong expressions
of CEACAM5 [29]. Therefore, it offers a target for blocking
tumor immune escape. We showed here that mAb CC4 could
markedly enhance NK cytotoxicity against colorectal cancer cells
Figure 6. mAb CC4 blocked the suppression of NK killings induced by over-expression of CEACAM5 in colorectal cancer cells.
Forced expressions of CEACAM1 and CEACAM5 in HCT-15 cells were confirmed by flow cytometry (A). Stable transfectants were then subjected to NK
cytotoxicity assays using CD56+CD16+ NK cells (B) and CD56+CD16- NK cells under different ratios of numbers of target cells to that of effector cells
(C and D). Significant differences between mAb CC4 treated or RACEA-treated groups and the corresponding control groups were indicated by
double stars (**P,0.01).
doi:10.1371/journal.pone.0021146.g006
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CEACAM1 with NK CEACAM1. Monoclonal antibodies against
CEACAMs may provide new routes for cancer immune therapy.
Materials and Methods
Ethics Statement
Human tumor tissues and normal tissues were collected under a
protocol approved by the Institutional Review Board of the Insti-
tute of Biophysics, Chinese Academy of Sciences, that included the
use of biopsy material for further biological studies. In accordance,
the tissue donor gave a written informed consent that included the
use of tumor material and normal tissue for cell banking as well as
for the establishment of the tumor cell line and use of the cells for
further studies. Maintenance of mice and experimental procedures
were reviewed and approved by the Animal Welfare and Research
Ethics Committee of the Institute of Biophysics, Chinese Academy
of Sciences (Permit No.: SYXK2009-103). Mice were housed in a
specific pathogen-free barrier facility. Surgeries were performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering. All animals were euthanized after the experi-
ments to allow the collection of tumor tissues.
Cells, tissues and animals
All the cell lines were obtained from American Type Culture
Collection (Rockville, MD). Both CD56+CD16+ and CD56+CD
16- Human NK cells were sorted out from human blood-derived
peripheral blood mononuclear cells (PBMCs) using magnetic cell
sorting kits (Miltenyi Biotec, Germany). Briefly, PBMCs were
isolated by density gradient centrifugation using Ficoll-Paque (GE
Healthcare). The isolation of CD56+CD16+ NK cells was per-
formed in a two-step procedure. First, non-NK cells such as T cells,
B cells, dendritic cells, stem cells, monocytes, granulocytes, and
erythroid cellswereindirectly magnetically labeled with a cocktail of
biotin-conjugated antibodies against lineage-specific antigens and a
cocktail of MicroBeads, Upon subsequent magnetic separation of
the cells over a MACS Column that was placed in a magnetic field,
the magnetically labeled non-NK cells were retained within the
column while the unlabeled NK cells ran through. In the second
step, the pre-enriched NK cells were directly labeled with CD16
MicroBeads. Upon subsequent magnetic separation, the CD56+
CD16+ NK cells were eluted after removing the column from the
magnetic field. Similar methods were also used to isolate CD56+
CD16- NK cells. Non-NK cells and CD56+CD16+ NK cells were
depleted in the first step, and CD56+CD16- NK cells were then
directly labeled with CD56 MicroBeads and magnetically separated
in the second step. Both kinds of NK cells were cultured in alpha-
MEM with 10% horse serum and 1 mM glutamate, 1 mM non-
essential amino acid, 1 mM sodium pyruvate, 2610
25 M b-ME
and 50 U/ml recombinant human Interleukin-2. Human tumor
tissues were obtained from the tissue bank of the 301 Hospital in
Beijing, and normal tissues are obtained from the Beijing Legal
Medial Institute. 6–8 week-old female inbred BALB/c mice and
nude mice were obtained from the Animal Center of the Chinese
Academy of Medical Science, Beijing.
Antibodies and constructs
The primary antibodies used were polyclonal rabbit-anti-human
Carcinoembryonic antigen (DakoCytomation), anti-HLA-ABC (Ab-
cam), isotype-matched IgG (Sigma). Mouse mAb CC4 was purified
from ascites using protein A-Sepharose. Corresponding species-
specific biotinylated, FITC-conjugated (Dianova, Hamburg, Ger-
many) or HRP-conjugated (Pierce) secondary antibodies were used.
For labeling antibodies, one mg of purified CC4 antibodies was
labeled with Cyanine 5 using the Cy5 NHS ester (Amersham).
pcDNA3.1-CEACAM5, pcDNA3.1-CEACAM5DN and pcDNA
3.1-CEACAM1 are generous gifts from Dr. Ofer Mandelboim
(Hebrew University of Jerusalem). Different fragments of CEA-
CAM5 extracellular domains were cloned from CEACAM5 cDNA
into pET32a correspondingly to generate the constructs expressing
recombinant CEACAM5 fractions fused with Trx-His6-S tag. Full-
length mutants of CEACAM5 and CEACAM1 were generated by
standard over-lapping PCR.
Generation and screening of monoclonal antibody
1610
7 of human colorectal cancer cells, LS174T, were injected
intraperitoneally with Freund complete adjuvant into 6-week-old
BALB/c mice and boosted four times at two-week intervals, and
then their spleens were taken for hybridoma preparation by fusion
with mouse SP2/0-Ag14 myeloma cells as described [30]. ELISA
was used to select antibodies binding to LS174T cells. Briefly, cells
were grown in 96-well plates and fixed in pre-chilled methanol/
acetone (1:1). Plates were then blocked in 5% non-fat milk/PBS
and incubated with hybdridoma culture supernatants, followed by
washings and incubation with HRP-conjugated anti-mouse IgG
(Sigma). Color reaction, developed by adding TMB (Sigma) as
substrate, was measured by a BioRad ELISA reader at 450 nm.
Flow cytometry
Detached cells were processed to obtain single-cell suspensions
followed by staining with CC4 or anti-CEA antibodies on ice for
40 minutes. After 3 times of washing with PBS containing 0.3%
bovine serum albumin, cells were incubated with corresponding
fluorescein isothiocyanat (FITC) conjugated anti-mouse IgG
(Sigma) on ice for 30 minutes, then washed and analyzed using
a FACS Calibur flow cytometry system (Becton Dickinson, San
Jose, CA).
Immunoprecipitation and antigen identification
LS174T cells were collected and lysed in ice-cold RIPA buffer
[Tris-HCl 50 mM pH 8.0, NaCl 150 mM, EDTA 1 mM, NP-40
1%, Glycerol 10%, PMSF 100 mg/ml]. After centrifugation the
supernatant was pre-cleared with protein A-Sepharose (Sigma),
and diluted cell lysate (1 mg/ml of total proteins) was then
immunoprecipitated with either mAb CC4 or mIgG at 4uC for
2 h, followed by incubation with protein A-Sepharose for 1 h.
After extensively washings, immunoprecipitates were analyzed by
Western blot assay.
Antigen identification and proteomic analysis were performed
as described by Gharahdaghi et al [31]. Briefly, protein captured
by mAb CC4 was separated by 10% SDS-PAGE and visualized by
silver staining. Protein bands smearing from 140 kD to 110 kD
were excised manually and standard trypsin digestion and sub-
sequent liquid chromatography-mass spectrometric (LC-MS) anal-
ysis of the protein digests were performed. The peptide sequences
thus obtained were searched for in the NCBI and SwissProt Data-
banks using Mascot Deamon software (Matrix Science, London,
UK).
CFSE staining
In proliferation assay, LS174T cells were resuspended in PBS/
0.1% BSA at a concentration of 1610
6 cells/ml and labeled with
10 mM CFSE at 37uC for 10 minutes. Cells were then seeded in 6
well plates (1.5610
6 cells/well), and 6 hours later different con-
centrations of mAb CC4 or mIgG were added. 18 hours later,
cells were harvested and analyzed using a flow cytometer with
488 nm excitation and emission filters appropriate for fluorescein.
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Cell transmigration was assayed using transwells (8-mm pore
size; Corning Costar, NY). Cells were resuspended in serum-free
medium containing 1% BSA and then added to the upper chamber
(10000/well) in the presence of either mAb CC4 or mIgG. Lower
chambers contained 20% fetal calf serum (FCS). After incubation at
37uC overnight, cells remained at the upper surface of the mem-
brane were removed using a swab, while the cells that migrated to
the lower membrane surface were fixed with ethanol and stained
with Giemsa solution. Cells migrating through the filter were counted
and the number of migrating cells per optic field (620) was plotted.
Cell aggregation assay is based on a previously described method
[32]. Subconfluent cell layers were detached by incubation in
Hank’s Buffered Salt Solution (HBSS) containing 1 mM EDTA.
Cells were washed, resuspended (5610
5 cells/ml) in HBSS/BSA by
three passages through an 18-gauge needle and then seeded in a 24-
well plate previously coated with 2% BSA in HBSS and allowed to
aggregatefor3 hoursinthe presenceofmAbCC4ormIgGat37uC
on a rotating shaker (80 rpm). The reaction was stopped by the
addition of 0.5 ml of 25% glutaraldehyde per well. Aggregation was
quantified by counting representative aliquots from each sample.
The blockage of aggregation was quantified by the following for-
mula: % Single cells=NS/N06100, where Ns is the total number
of single cells, and N0 is the total number of cells. At least 600 cells
were counted from each sample.
ADCC and NK cytotoxicity assay
The method of LDH release was used in both cytotoxicity
analyses. Briefly, for ADCC assay 5000 cells of LS174T or A375
were grown in 96-well plate as the target cells. 5610
5 mouse
spleen cells, isolated from BALB/c mice, were added (T:E=1:100)
with different concentrations of mAb CC4 or mIgG. For NK
cytotoxicity assay, 10, 000 cancer cells were used as target cells and
10, 000 or 15, 000 NK cells (T:E =1:1 or 1:1.5) were added in the
presence of CC4 F(ab)2 or anti-CEA polyclonal antibody RACEA.
Four hours later, enzymatic activity of LDH released from target
cells were measured by CytoTox-ONE Homogeneous Membrane
Integrity Assay kit (Promega). Cytotoxicity was quantified by the
following formula: % cytotoxicity=(Exp – T spon – E spon) / (T
max – T spon), in which T spon and E spon are the spontaneous
LDH release of target and effector cells respectively, and T max is
the maximum of LDH release of target cells, obtained by lysing
them before testing.
In vivo optical imaging of tumor-bearing mice
Subcutaneous (s.c.) injection of 2610
7 A549 cells suspended in
200 ml of PBS into the right flank of female athymic nude mice
resulted in formation of tumors after 4–6 weeks. The mice bearing
s.c tumors at diameter of 6–8 mm were used for imaging experi-
ments. They received intravenous (i.v.) injection of Cy5-labeled
CC4 antibody at 20 mg/200 ml for each mouse or the isotype
Cy5-IgG negative control at a similar concentration. Fluorescence
reflectance imaging was performed using a Hamamatsu optical
imaging system as described previously [33]. For quantifying tumor
contrast, the mean fluorescence intensities of the tumor area (T) and
that of the distant skin area (S) were calculated; dividing T by S
produced the ratio between tumor tissues and background level.
Human colorectal cancer xenografts
Xenografts of human colorectal cells were produced by injecting
LS174T cells (1610
7 resuspended in PBS) subcutaneously into the
back of 6-week-old BALB/c nude mice. When tumors reached a
diameter of 3 to 5 mm, the mice were grouped (7 mice per group)
and administrated intraperitoneally with purified mAb CC4 at a
dose of 5 mg/kg or PBS, twice per week for 21 to 28 days. Tumor
size was measured twice per week and tumor volume was deter-
mined according to the equation: tumor volume=width
26length6
(p/6). The 2-tailed Student t-test was used for statistical analysis.
Statistical analysis
All values are representative of experiments performed in tripli-
cate. The graphical results are expressed as the mean 6 SD.
Paired t test methods were used to compare differences between
groups in various experiments. The criterion for statistical signi-
ficance is defined as p,0.01 (double stars) or 0.01,p,0.05 (single
star).
Additional experimental methods can be found in Supplemental
Materials and Methods (Text S1).
Supporting Information
Figure S1 mAb CC4 repressed cell cycle transition of
LS174T cells. LS174T cells were serum-starved for 48 hours to
synchronize cell cycle and then treated with indicated concentra-
tions of mAb CC4 or normal murine IgG for 12 hours and sub-
jected to cell cycle analysis. Percentages of cells remained in G1, S
and G2 phases were calculated by the software of Cylchred and
presented in (A)–(D).
(TIF)
Figure S2 mAb slightly induced apoptosis of LS174T
cells. Cells were treated with 50 mg/ml mAb CC4 or mIgG for
24 hours and then subjected to TUNEL assay to label the DNA
strand breaks, the indicator for apoptosis. The nuclei were stained
by DAPI. Typical optic fields (610) of treated cells were presented
in (A) and apoptotic cells were seen in fluorescent green. The mean
values of numbers of apoptotic cells per 100 cells were presented in
bar graph (B). At least ten fields were calculated and included in
statistic analysis.
(TIF)
Figure S3 mAb CC4 inhibited colorectal cancer cell
migration. Transmigration assays were applied using Lovo cells
(A) and Colo-205 cells (B) in the presence of indicated con-
centrations of mAb CC4 or normal murine IgG. The number of
cells migrating through the filter was countered and plotted as the
number of migrating cells per optic field (620).
(TIF)
Table S1 Flow cytometry and immunofluorescent anal-
ysis of mAb CC4 immunoreactivity to human cancer cell
lines.
(DOCX)
Table S2 Immunohistochemical analysis of the speci-
ficity of mAb CC4 for normal and tumor human tissues.
(DOCX)
Table S3 Fluorescent intensity of mAb CC4 and anti-
HLA-ABC immunostaining against human colorectal
cancer cell lines.
(DOCX)
Text S1 Supplemental Materials and Methods
(DOCX)
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